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The ISBT 700 series of low-incidence and 901 
series of high-incidence blood group antigens
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The International Society of Blood Transfusion Working Party 
on Terminology for Red Cell Surface Antigens developed a 
terminology that brought order to the chaos of antigen names. 
They classified antigens into three categories: systems, collections, 
and series. This review summarizes the early decisions of the 
Working Party with an emphasis on the 700 series of low-
incidence antigens and 901 series of high-incidence antigens. 
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By 1980, the number of blood group antigens that had 
been described and the multitude of creative names used were 
becoming overwhelming. An antibody or antigen could be 
found in more than one laboratory and, if an effort was not 
made to perform cross testing, could be assigned a different 
name. Examples include the finding that Rla was the same 
as Lsa, and Lan was the same as Gna and So. Similarly, two 
different antigens could bear the same name, e.g., Hughes 
(Hga) is an antigen in the Diego system (DI12) and Hughes 
is an antigen in the Lutheran system (LU13). Other examples 
of inadvertent, unfortunate symbol choices were (1) the 
alphabetically similar sD in the MNS system (MNS23) and the 
polyagglutination-related antigen Sda, and (2) the phonetically 
similar Emm (901008) and M (MNS1). The manner in 
which an antibody or antigen was labeled could sometimes 
only be deciphered by the worker who wrote the label. It 
was obvious that a system was needed to bring order to the 
growing chaos. The principal force in the organization of an 
International Society of Blood Transfusion (ISBT) Working 
Party on Terminology for Red Cell Surface Antigens was the 
ISBT Working Party on Automation and Data Processing. 
The first Working Party consisted of 32 eminent international 
investigators, one of whom was John Moulds. John was a 
specialist in all blood groups but had a particular fondness 
for the orphan “private” or “uncommon,” and “public” or 
“common” antigens. He had agreed to write a review for 
Immunohematology on this topic, but his premature death 
prevents us from knowing what he had in mind to share. Out 
of respect for John, I write this review knowing that it is in no 
way a substitute for what he would have imparted.
Order From Chaos
At their first meeting in Montreal, at the ISBT biannual 
congress in 1980, the Working Party began to develop a 
scheme for naming blood group antigens that was both eye 
and machine readable, in keeping with the genetic basis 
of blood groups, and infinitely expandable. The priority of 
the group was to develop a scheme to name and to assign a 
number for each blood group antigen—not to replace the 
original names, which are easier to remember, but to have 
standard alternatives for use in computers. The Working Party 
decided to follow the rules of the Human Gene Nomenclature 
group and agreed to no longer use Greek letters, superscripts, 
and subscripts, in favor of using uppercase Roman alphabet 
letters and Arabic numerals in naming blood group antigens. 
The second meeting was held in New York City in 1981, after 
which a preliminary report was published with recommended 
numbers for 28 antigens in nine systems.1 This ingenious 
scheme, albeit considerably expanded, is still in use today.
Scheme for Categorizing Antigens
By definition, all blood group antigens must be defined 
serologically by the use of a specific antibody. All antigens 
receiving ISBT numbers must have been shown to be 
inherited characters. After the sixth meeting, held in 1988 
at the 20th ISBT Congress in London, the Working Party 
wrote a monograph providing their rationale and guidelines 
for the official numeration of new specificities.2 The Working 
Party classified serologically determined antigens into three 
categories: systems, collections, and series. Obviously, the 
classifications were made based on knowledge of the time and 
were considered to be “carved in soap rather than in stone.”3
Blood Group Systems
A blood group system is a discrete genetic entity under the 
control of a single gene or by contiguous, largely homologous 
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genes that had been differentiated from each other. The 
different antigens within a system are encoded by alternative 
forms of the gene. The number of discrete antigens in a system 
currently ranges from 1 to more than 50.4 A six-digit number 
for use in computers was devised; the first three numbers 
represent the system (e.g., 001 for ABO, 002 for MNS) and the 
remaining three the specificity (e.g., 001001 for A, 001002 for 
B, 002001 for M, 002002 for N, 002003 for S).2
Collections
Antigens that did not belong in a system, because 
their controlling genes were not known, were gathered 
into “collections.” Antigens placed on one collection had a 
serologic, biochemical, or genetic connection. This category 
was considered a temporary classification, pending conclusive 
evidence that the members of any one collection are controlled 
by a single gene different from those of all of the systems. This 
was indeed the case, and many collections have been promoted 
to system status. To allow for expansion of systems (beyond all 
expectations), numbers for collections commenced at 201; the 
first three numbers represent the collection and the last three 
the specificity. For example, 201001 for Ge2, 201002 for Ge3, 
201003 for Ge4, 202001 for Cra, and 202002 for Tca.2
Series
Two series were formed to accommodate orphan antigens 
of low or high incidence. The ISBT Working Party defines 
a low-incidence antigen as one that occurs in less than 1 
percent of people in most populations studied, whereas a high-
incidence antigen is defined as one that occurs in more than 
90 percent of people in most populations studied. Again, to 
allow for expansion and to adequately separate the systems, 
collections, and series, numbers for the low-incidence series 
started with 700 and the numbers for the high-incidence series 
initially commenced at 900. The first three numbers represent 
the series and the last three the specificity. As a result of the 
formation of the collections category, the 700 series was only 
slightly affected, but the 900 series was much depleted and 
was replaced by the 901 series.2 Both the 700 and 901 series 
were considered temporary classifications that might be called 
holding files.
The 700 Series of Low-Incidence Antigens
In keeping with the temporary nature of this classification, 
36 of the 55 antigens have been upgraded from the 700 series 
to collections or systems. When an antigen is promoted, its 
associated 700 series number is made obsolete. Table 1 lists 
the obsolete numbers, antigen symbols and names, current 
ISBT numbers, and the reason why each was made obsolete. 
As of the last meeting of the Working Party in July 2010, 18 
Table 1. 700 series of obsolete numbers, antigen symbols and 
names, current numbers, and reasons why they were made obsolete
Obsolete no. Symbol Name Current no.* Reason why made obsolete
700001 Wra Wright 010003 In Diego system
700004 Swa Swann 010013 In Diego system
700007 Lsa Lewis 020006 In Gerbich system
700008 Tra Traversu 010019 In Diego system
700009 Wb Webb 020005 In Gerbich system
700010 Bpa Bishop 010010 In Diego system
700011 Or Oriss 002031 In MNS system
700012 Gf Griffiths … Control reagent no longer 
extant
700013 Wu Wulfsberg 010009 In Diego system
700014 Jna Jensen 010017 In Diego system
700015 Rd Radin 013004 In Scianna system
700016 Heibel … Control reagent no longer 
extant
700020 Ana Ahonen 020007 In Gerbich system
700022 Moa Moen 010011 In Diego system
700023 Hey Hey … Control reagent no longer 
extant
700024 Rla Rosenlund … Same as Lsa
700025 Ina Indian 023001 Antithetical to Inb; in Indian 
system
700026 Fra Froese 010020 In Diego system
700027 Rba Redelberger 010006 In Diego system
700029 Vga Van Vugt 010013 In Diego system
700030 Wda Waldner 010005 In Diego system
700031 Dha Duch 020008 In Gerbich system
700032 POLL Pollio … Control reagent no longer 
extant
700033 Osa 002038 In MNS system
700034 Hga Hughes 010012 In Diego system
700035 Tcb 021003 In Cromer system
700036 Tcc 021004 In Cromer system
700037 NFLD Newfoundland 010016 In Diego system
700038 Hov … Same as Wu
700041 SW1 010021 In Diego system
700042 WES (or 
WESa)
021008 In Cromer system
700043 Ola Oldeide 030002 In the RhAG system
700046 BOW Bowyer 010015 In Diego system
700048 FPTT 004050 In Rh system
700051 ELO 010008 In Diego system
700053 LOCR 004055 In Rh system
700055 WARR Warrior 010007 In Diego system
Some antigens were upgraded to collections before finally residing in a 
system.
M.E. Reid
IMMUNOHEMATOLOGY, Volume 27, Number 4, 2011 133
ISBT 700 and 901 series of antigens: a review
antigens remain in the 700 series of low-incidence antigens 
(Table 2).4 For each of these antigens, this table lists the specific 
700 number, its symbol, and its name.
How Low-Incidence Antigens Are Found
An antibody to a novel low-incidence antigen is revealed 
when red blood cells (RBCs) expressing that antigen are 
agglutinated unexpectedly by plasma in one of the following 
scenarios. The antibody
1. causes hemolytic disease of the fetus and newborn 
(HDFN)
2. causes an incompatible crossmatch
3. is found in serum known to contain one or more 
antibodies to low-incidence antigens—the so-called 
multi-low serum
4. is found as a contaminant in a blood typing 
reagent, giving an unexpected reaction during RBC 
phenotyping.
Criteria for Inclusion in the 700 Series
The following criteria are in effect for an uncommon 
antigen to join the 700 series:
1. The antigen must have an incidence of less than 1 
percent in most populations tested.
2. The antigen must be distinct from antigens of the blood 
group systems, the collections, and the other numbered 
low-incidence antigens of the 700 series.
3. It must be an inherited character.
4. Plasma containing the antibody and RBCs expressing 
the antigen must be available so that further examples 
can be identified.
The 901 Series of High-Incidence Antigens
Ten of the 16 antigens in the 901 series of high-incidence 
antigens have been upgraded to collections or systems. Table 
3 lists the obsolete numbers, antigen symbols and names, 
current ISBT numbers, and the reason why each was made 
obsolete. As of the last meeting of the Working Party, in July 
2010, eight orphan antigens remain in the 901 series of high-
incidence antigens (Table 4).4 For each of these antigens, this 
table lists the specific 901 number, its symbol, and its name. 
In January 2012, based on three reports in Nature Genetics,5–7 
Jra and Lan antigens were provisionally upgraded to their own 
blood group systems. 
How High-Incidence Antigens Are Found
An antibody to a novel high-incidence antigen is revealed 
when RBCs expressing that antigen are agglutinated 
unexpectedly by plasma in one of the following scenarios. The 
antibody
1. causes an incompatible crossmatch
Table 2. Antigens of low incidence currently in the 700 series



















Table 3. 901 series of obsolete numbers, antigen symbols and 
names, current numbers, and reasons why they were made obsolete
Obsolete no. Symbol Name Current no. Reason why made obsolete
901001 Vel 212001 In Vel collection
901002 Lan Langereis 033001 Formed a new system
901004 Joa Joseph 014005 In Dombrock system
901005 Jra 032001 Formed a new system
901006 Oka 024001 In Ok system
901007 JMH John Milton Hagen 026001 In John Milton Hagen 
system
901010 Wrb 010004 In Diego system
901011 MER2 025001 In Raph system
901013 Duclos 030001 In RhAG system
901015 ABTI 212002 In Vel collection
Table 4. Antigens of high incidence currently in the 901 series
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2. is found during the investigation of a transfusion 
reaction
3. causes a positive direct antiglobulin test on fetal RBCs 
or mild HDFN. 
It is worth noting that, with the exception of anti-MAM, 
antibodies to antigens remaining in the 901 series have caused 
mild HDFN requiring nothing more than phototherapy.
Criteria for Inclusion in the 901 Series
The following criteria are in effect for a common antigen 
to join the 901 series:
1. The antigen must have an incidence of greater than 90 
percent in most populations tested.
2. The antigen must be distinct from antigens of the blood 
group systems, the collections, and the other numbered 
high-incidence antigens of the 901 series.
3. It must be an inherited character.
4. Plasma containing the antibody and RBCs lacking the 
antigen must be available so that further examples can 
be identified.
Naming an Antigen
If you are lucky enough to find a new antigen, it is 
important to ask the appropriate member of the Working Party 
for a provisional ISBT number. This prevents duplication of 
numbers, and the inadvertent, unfortunate use of a name as 
described above should be avoidable. At the next biannual ISBT 
Congress, when the Working Party meets, assuming there is 
agreement, the number is ratified. In this way, a structured, 
standard terminology is maintained. Instructions for obtaining 
an ISBT number for an antigen and contact information are 
provided in the latest update report of the Working Party,4 in 




In 1992, John Moulds coauthored a review with Peter 
Issitt in which they described the salient features of the ISBT 
alternative terminology to assist readers of Transfusion who 
might encounter the then-new terms.9 At that time 36 antigens 
were in the 700 series and 12 antigens in the 901 series. In 
20 years, four new antigens have been added to the 700 and 
three to the 901 series. As predicted, many antigens in these 
“holding tanks” of the ISBT series have been promoted to 
systems or collections; the number has dropped to 18 in the 
700 series and 6 in the 901 series. With knowledge of genes 
and our ability to test DNA, it is likely that the remaining 
orphans will eventually find homes.
John Moulds had an encyclopedic memory. He would 
warmly remember each orphan antigen-antibody pair and 
regale colleagues with stories about who found the first (or 
first few) case(s), when and where it was found, how it was 
named, the clinical scenarios, and adventures of getting blood 
samples from family members, sometimes in far-flung parts 
of the world. He was always ready with a yarn and loved to 
share his knowledge. Until shortly before his death, John was 
convinced he would write a review about orphan antigens 
for Immunohematology. Indeed, his desk was piled high 
with reprints ready to be read. We thought it appropriate 
to include a review, albeit short, to appear in this issue 
dedicated to him. Landsteiner has been called the “Father of 
Immunohematology”; I like to think that John was the father 
of orphan antigens in the ISBT 700 series and 901 series.
See Table 5 for information on, including characteristics 
of, the ISBT 700 series. This information has also been 
provided as a removable educational insert in the centerfold 
of this issue.
Note: Information on the characteristics of the antigens 
and antibodies in the ISBT 700 series has been provided as 
a removable educational insert in the centerfold of this issue.
Cynthia Flickinger/Managing Editor
M.E. Reid
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